Cargando…

Venetoclax in the Treatment of Chronic Lymphocytic Leukemia: Evidence, Expectations, and Future Prospects

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the western adult population; it is also prevalent worldwide. The B cell lymphoma-2 (BCL-2) family proteins play a key role in regulating intrinsic apoptosis and, in many cancers, are the main culprits behind tumor survival an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tariq, Saba, Tariq, Sundus, Khan, Maliha, Azhar, Aysha, Baig, Mukhtiar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2020
Materias:	Miscellaneous
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389877/ https://www.ncbi.nlm.nih.gov/pubmed/32742874 http://dx.doi.org/10.7759/cureus.8908

Ejemplares similares

Association of serum osteoprotegerin with severity of chronic liver disease in female patients: A potential biomarker
por: Tariq, Saba, et al.
Publicado: (2020)

Status of bone health and association of socio-demographic characteristics with Bone Mineral Density in Pakistani Females
por: Tariq, Saba, et al.
Publicado: (2019)

Knowledge, Awareness, and Practices Regarding the Novel Coronavirus Among a Sample of a Pakistani Population: A Cross-Sectional Study
por: Tariq, Saba, et al.
Publicado: (2020)

Association of serum levels of Visfatin, Intelectin-1, RARRES2 and their genetic variants with bone mineral density in postmenopausal females
por: Tariq, Sundus, et al.
Publicado: (2022)

Evaluation of Cognitive levels and Item writing flaws in Medical Pharmacology Internal Assessment Examinations
por: Tariq, Saba, et al.
Publicado: (2017)

Mid-luteal estradiol levels of poor/good responders and intracytoplasmic sperm injection
por: Rehman, Rehana, et al.
Publicado: (2017)

Association Between Vitamin D and Resistin in Postmenopausal Females With Altered Bone Health
por: Tariq, Sundus, et al.
Publicado: (2021)

Osteoprotegerin genetic polymorphisms and their influence on therapeutic response to ibandronate in postmenopausal osteoporotic females
por: Tariq, Saba, et al.
Publicado: (2023)

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
por: Schieber, Michael, et al.
Publicado: (2019)

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
por: Thompson, Meghan C., et al.
Publicado: (2022)

Successful Retreatment With Venetoclax in a Patient With Chronic Lymphocytic Leukemia
por: Jackson, Ross A., et al.
Publicado: (2022)

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
por: Muhowski, Elizabeth M., et al.
Publicado: (2022)

Relationship of Serum Leptin and Reproductive Hormones in Unexplained Infertile and Fertile Females
por: Baig, Mukhtiar, et al.
Publicado: (2019)

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
por: Herling, Carmen D., et al.
Publicado: (2018)

Venetoclax: a real game changer in treatment of chronic lymphocytic leukemia
por: Molica, Stefano
Publicado: (2020)

Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
por: Waggoner, Matthew, et al.
Publicado: (2022)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
por: Samra, Bachar, et al.
Publicado: (2020)

Serum Leptin Levels in Polycystic Ovary Syndrome and Its Relationship with Metabolic and Hormonal Profile in Pakistani Females
por: Baig, Mukhtiar, et al.
Publicado: (2014)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014)

P641: REAL-WORLD DURATION OF VENETOCLAX TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA
por: Teschemaker, Anna, et al.
Publicado: (2023)

Venetoclax: A Novel Treatment for Patients With del(17p) Chronic Lymphocytic Leukemia
por: Borg, Michelle A., et al.
Publicado: (2017)

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
por: Huber, Henriette, et al.
Publicado: (2017)

Can Treatment with Venetoclax for Chronic Lymphocytic Leukemia (CLL) Result In Autoimmune Hemolytic Anemia?
por: Abdel-Samad, Nizar, et al.
Publicado: (2021)

Targeting Autophagy Triggers Apoptosis and Complements the Action of Venetoclax in Chronic Lymphocytic Leukemia Cells
por: Avsec, Damjan, et al.
Publicado: (2021)

Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia
por: Samuels, Courtney, et al.
Publicado: (2021)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
por: Handunnetti, Sasanka, et al.
Publicado: (2021)

Concept mapping improves academic performance in problem solving questions in biochemistry subject
por: Baig, Mukhtiar, et al.
Publicado: (2016)

Operative expectations for Mohs surgery in patients with chronic lymphocytic leukemia: A multicenter retrospective cohort study
por: Hamel, Remi K., et al.
Publicado: (2023)

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
por: Yi, Xue, et al.
Publicado: (2022)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
por: Ferrarini, Isacco, et al.
Publicado: (2022)

Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia
por: Frustaci, Anna Maria, et al.
Publicado: (2022)

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
por: Izutsu, Koji, et al.
Publicado: (2023)

Successful treatment of relapsed chronic lymphocytic leukemia with venetoclax in a patient with severe chronic kidney disease
por: Sugiura, Hiroyuki, et al.
Publicado: (2022)

Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report
por: Wang, Lei, et al.
Publicado: (2021)

A novel mutation in the Lipase H gene underlies autosomal recessive hypotrichosis and woolly hair
por: Tariq, Muhammad, et al.
Publicado: (2012)

Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia
por: Khan, Maliha, et al.
Publicado: (2017)

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
por: Mato, Anthony R., et al.
Publicado: (2018)

Treatment with Venetoclax for Chronic Lymphocytic Leukemia with the Highest Known White Blood Cell Count: Safe and Effective
por: Sönmez, Mehmet, et al.
Publicado: (2021)

Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
por: Barbier, Michaela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b65eu314ed1v7b5je71u5hes9o